Product
Supplier
Encyclopedia
Inquiry
Home > Biochemical Engineering > Polypeptide > Tirzepatide for Sale > Tirzepatide with 99% purity GLP-1 API Powder Bulk Wholesale Raw Material
Tirzepatide with 99% purity GLP-1 API Powder Bulk Wholesale Raw Material buy - large image1
Tirzepatide with 99% purity GLP-1 API Powder Bulk Wholesale Raw Material buy - image1
Tirzepatide with 99% purity GLP-1 API Powder Bulk Wholesale Raw Material buy - image2
Tirzepatide with 99% purity GLP-1 API Powder Bulk Wholesale Raw Material buy - image3
Tirzepatide with 99% purity GLP-1 API Powder Bulk Wholesale Raw Material buy - image4
Tirzepatide with 99% purity GLP-1 API Powder Bulk Wholesale Raw Material buy - image5

Tirzepatide with 99% purity GLP-1 API Powder Bulk Wholesale Raw Material

TDS 2100 Inquiries

Unit Price: Get Latest Price
CAS No.:

2023788-19-2

Grade:

Pharmaceutical Grade

Content:

99%

Port:

Shanghai

Brand:

Thinheal/Tasln

Packaging:

50gram/bottle

Price valid (until):

2026-05-29

Company Type:
Manufactory
Location:
China
Payment Terms:
TT against copy of documents
Average Lead Time:
7 days
Qualification:
Main Products:

Semaglutide,Retatrutide,Tirzepatide,Linaclotide

  • Product Details

  • Seller Information

  • Inquiry History

  • Description


    Product Detail 


    Product Name Tirzepatide
    Cas Number 2023788-19-2
    Molecular Formula C225H348N48O68
    Molecular Weight 4813.24
    Appearance White powder
    Purity 99%+
    Storage Store at -20℃ degrees Celsius in a dry and cool place.


      Product Picture  


    Shop Tirzepatide with 99% purity GLP-1 API Powder Bulk Wholesale Raw Material-Detailed Image 1


      Product Usage  


    Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.

    This medication is designed to improve glycemic control in people with type 2 diabetes by targeting both the GIP and GLP-1 receptors. By stimulating these receptors, tirzepatide can increase insulin secretion and decrease glucagon secretion in a glucose-dependent manner, helping to lower blood sugar levels.

    Clinical trials have shown promising results in terms of reducing HbA1c levels and body weight in individuals with type 2 diabetes. Tirzepatide is being studied in various dosages and formulations to determine its effectiveness, safety, and potential benefits for people with diabetes

    NOTE: This product was prepared by chemical synthesis. Used only for research. Not for human use.


     FAQ 


    Q1: May I get one sample before placing order?

    Re: Yes, Sample are available. For normal products, samples are for free and you just need to bear the freight; For those high value products, you just need to freight and certain product cost. When we both cooperate for some times or when you are our VIP customer, free sample will be offered when you need.

    Q2: Which payment is available for your company?

    Re: T/T, PayPal,bank transfer etc. You can choose the one which is convenient for you.

    Q3: How and when can I get my goods after payment?

    Re: For small quantity products, they will be delivered to you by international courier(DHL, FedEx, TNT etc.) or by air. Usually it will cost 5-7days that you can get the goods after delivery.For large quantity products, shipping by see is worthwhile.It will cost 15 to 30 days to come to your destination port, which depends on where the port is.

    Q4: Is there any possible to use my appointed label or package?

    Re: Yes. If needed, we'd like  to do that.


     Company Profile 


    Hangzhou Thinheal Pharma-Tech Co., Ltd. was established in 2019. It is a biopharmaceutical company that combines independent R&D, production, sales and customized research and development and production of peptide products. The core management team is composed of professionals with a pharmaceutical background and nearly 20 years of management experience in the peptide industry. Thinheal has built a R&D center and a production base. The total production capacity of chemically synthesized peptides has now reached several tons, ranking at the forefront of the industry.

    The company has a complete and efficient peptide R&D, production and sales system, and provides a full range of peptide industrialization services, including peptide API R&D and production business, peptide customized R&D and production (CDMO) business, and beauty peptide research and development and production business. The company's revenue is mainly from peptide API business. Peptide API products mainly include more than 20 varieties such as semaglutide, tirzepatide, liraglutide, etc., among which semaglutide, tirzepatide and other varieties have completed the US FDA DMF filing. The CDMO business includes project-based entrusted research and development, entrusted production and sales. The main customers of the CDMO business are innovative drug companies and scientific research institutions, among which some pharmaceutical companies have cooperated with Thinheal since the product development stage and have established a solid cooperative relationship.


      Company's Pictures  


    Shop Tirzepatide with 99% purity GLP-1 API Powder Bulk Wholesale Raw Material-Detailed Image 2 Shop Tirzepatide with 99% purity GLP-1 API Powder Bulk Wholesale Raw Material-Detailed Image 3

    ECHEMI Editorial Reference

    Tirzepatide (LY3298176) was developed as a dual agonist to both GLP-1 and gastric inhibitory polypeptide (GIP) receptors (Frias et al., 2018). Similar to GLP-1, GIP is an incretin hormone that functions to induce insulin secretion.

    Certificates

    Basic Info
    Product Name:

    Tirzepatide

    Other Name:

    LY3298176;

    CAS No.:

    2023788-19-2

    Molecular Formula:

    C225H348N48O68

    Molecular Weight:

    4813

    EC Number:

    200-001-8

    Categories:

    Polypeptide

    Characteristics
    Appearance:

    White to off-white

    Research
    Class:

    Dual agonist — GIPR, GLP-1R

    Status:

    FDA-approved (Mounjaro / Zepbound)

    Mechanism:

    Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. A 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding for extended half-life (~5 days). Selectively activates both GIPR and GLP-1R signaling pathways.

    EC50 (Human GLP1R):

    0.934 nM

    EC50 (Human GIPR):

    0.0224 nM

    Source:

    Frias JP, et al. N Engl J Med. 2021;385(6):503-515.DOI

    FDA:

    Mounjaro, Zepbound (approved 2022-05-13)

    References
    ChEMBL:

    CHEMBL4297839

    DrugBank:

    DB15171

    KEGG DRUG:

    D11360

    PubChem:

    PubChem

    Disclaimer:

    Tirzepatide is approved as a prescription medicine (Mounjaro, Zepbound) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.

  • Seller Information
    Business Type:

    Manufactory

    Main Products:

    Semaglutide,Retatrutide,Tirzepatide,Linaclotide

    Location:

    8th Floor, Building 2, Phase 5, Xiasha Heda Pharmaceutical Valley, Qiantang District, Hangzhou, Zhejiang Province

    Payment Terms:

    TT against copy of documents

    Average lead Time:

    7 days

    Total Annual Revenue:

    $25 million-$50 million

    Total Employees:

    301-500

    Year of Establishment:

    2019

    Company Certificates
    • Hangzhou Thinheal PharmaWC WC
    • Hangzhou Thinheal PharmaGMP GMP

    杭州信海医药科技有限公司成立于2019年,是一家专注于多肽产品的研发、生产、销售与定制、研发生产相结合的生物医药企业。核心管理团

    队由具有深厚医药专业背景的专业人士组成。信海医药建有一个研发中心和两个生产基地,目前化学合成多肽总产能已达数吨级规模。


         公司具备完整高效的多肽研发、生产及销售体系,提供全方位的多肽产业化服务,包括原料药研发和生产业务、制剂研发业务、多肽定制研发生产(CDMO)业务、以及美容肽研发生产业务。现阶段产品主要包括司美格鲁肽、替尔泊肽、利那洛肽、瑞塔鲁肽等数十个品种,其中司美格鲁肽、替尔泊肽、利那洛肽等多个品种已完成美国FDA DMF备案。

         公司以固、液相结合的化学合成工艺手段为驱动,建有复杂多肽及类肽化学合成及修饰平台、多肽片段设计与合成技术平台、多分离手段纯化平台等完善研发体系,拥有一支130人以上研发队伍,博士、硕士学历人员占比近20%,核心研发团队拥有超过20年的多肽药物开发经验,具备深厚的专业背景和丰富的实践经验.

  • Inquiry History
    2100 Inquiries
    Country Product Purchase Quantity Date Posted
    United States

    Tirzepatide

    20 MG Oct 27, 2026
    Philippines

    Tirzepatide

    2 MT Oct 27, 2026
    Philippines

    Tirzepatide

    30 MG Oct 26, 2026
    Slovakia

    Tirzepatide

    1 G Oct 26, 2026
    France

    Tirzepatide

    1 KG Oct 25, 2026
    United States

    Tirzepatide

    2.5 MG Oct 25, 2026
    United Kingdom

    Tirzepatide

    5 MT Oct 25, 2026
    United Kingdom

    Tirzepatide

    6 MT Oct 24, 2026
    Peru

    tirzepatide

    10 MG Oct 21, 2026
    Puerto Rico

    tirzepatide

    40 MG Oct 21, 2026
    United States

    Tirzepatide

    10 MT Oct 21, 2026
    South Africa

    Tirzepatide

    1 MT Oct 20, 2026
    United States

    Tirzepatide

    5 KG Oct 20, 2026
    United States

    tirzepatide

    30 MG Oct 20, 2026
    United States

    Tirzepatide

    50 MG Oct 20, 2026
    Spain

    tirzepatide

    20 MG Oct 19, 2026
    United States

    tirzepatide

    30 MG Oct 19, 2026
    Philippines

    tirzepatide

    40 MG Oct 19, 2026
    United States

    tirzepatide

    50 MG Oct 19, 2026
    United States

    tirzepatide

    50 MG Oct 19, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.